Omega-3 Levels and Nicotine Dependence: A Cross-Sectional Study and Clinical Trial.

What Was Tested

Researchers studied Therapeutic nicotine (patch, non-peptide) in this randomized controlled trial publication.

High oxidative stress, which is caused by smoking, can alter omega-3 fatty acid concentrations.

Since omega-3 fatty acids play a role in dopaminergic neurotransmission related to dependence, it is important to understand their effects on nicotine dependence.

Who Took Part

According to the abstract, 171 individuals were involved.

By PubMed's age tags, the people studied were young adults, adults and middle-aged adults, both men and women.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Because people in this Therapeutic nicotine (patch, non-peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the individuals nor the staff measuring them knew who was on Therapeutic nicotine (patch, non-peptide), so expectations could not easily colour the readings.

Some individuals received a placebo instead of Therapeutic nicotine (patch, non-peptide), giving a reference point.

This research comprised 2 studies.

The first one consisted of a cross-sectional evaluation, in which the levels of the most important omega-3 fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), were compared between smokers and non-smokers in a sample of 171 individuals; of them, 120 were smokers and 51 were non-smokers.

The outcome was evaluated by means of psychometric and biological measures as well as self-reports of tobacco use.

What Was Measured

Topics PubMed links to this paper include Cross-Sectional Studies, Dietary Supplements, Docosahexaenoic Acids, Eicosapentaenoic Acid, Fish Oils, Smoking and Tobacco Use Disorder.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Therapeutic nicotine (patch, non-peptide) in 171 individuals.

Its findings take up roughly 3 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2016 (European addiction research), a journal based in Switzerland.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.